AUROBINDO PHARMA LTD. - 524804 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificates09-02-2024
09-02-2024
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Investor / Analyst meet08-02-2024
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Investor / Analyst meet08-02-2024
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Investor / Analyst meet08-02-2024
AUROBINDO PHARMA LTD. - 524804 - Record Date For The Payment Of Second Interim Dividend
Record Date for the payment of Second Interim Dividend, if any, for the financial year 2023-2407-02-2024
AUROBINDO PHARMA LTD. - 524804 - Corporate Action-Board to consider Dividend
The Board of Directors in its meeting to be convened on 10th February 2024 will also consider the payment of second interim dividend, if any, for the financial year 2023-24.07-02-2024
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Dividend Updates
The Board of Directors in its meeting convened to be held on 10th February 2024 will also consider the payment of second interim dividend, if any, for the financial year 2023-24.07-02-2024
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of investor call on 12th February 2024 at 8.30 AM (IST) on Q3 FY 2023-24 earnings05-02-2024
AUROBINDO PHARMA LTD. - 524804 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificates05-02-2024
Aurobindo Pharma Sells U.S. Subsidiary For $52 Million Plus Lease Payments
Eugia US Manufacturing LLC currently does not contribute to the overall consolidated revenue of Aurobindo Pharma and is a loss-making entity according to FY23 financial data.05-02-2024